A COVID-19 vaccine is a vaccine intended to provide acquired immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus causing coronavirus disease 2019 (COVID-19). Prior to the COVID-19 pandemic, there was an established body of knowledge about the structure and function of coronaviruses causing diseases like severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), which enabled accelerated development of various vaccine technologies during early 2020.On 10 January 2020, the SARS-CoV-2 genetic sequence data was shared through GISAID, and by 19 March, the global pharmaceutical industry announced a major commitment to address COVID-19
Components of the Book:
- Chapter 1
Current Status of COVID-19 Vaccine Development Focusing on Antigen Design and Clinical Trials on Later Stages
- Chapter 2
COVID-19 vaccine where are we now and where should we go
- Chapter 3
Vaccines for COVID-19
- Chapter 4
COVID-19 Vaccine Hesitancy Worldwide A Concise Systematic Review of Vaccine Acceptance Rates
- Chapter 5
COVID-19 vaccine acceptance among pregnant women and mothers of young children results of a survey in 16 countries
- Chapter 6
A COVID-19 Vaccine Big Strides Come with Big Challenges
- Chapter 7
COVID-19 Vaccines A Race Against Time in the Middle of Death and Devastation!
- Chapter 8
COVID-19 Vaccines (Revisited) and Oral-Mucosal Vector System as a Potential Vaccine Platform
- Chapter 9
COVID-19 preparedness capacity to manufacture vaccines, therapeutics and diagnostics in sub-Saharan Africa
- Chapter 10
Ongoing Clinical Trials of Vaccines to Fight against COVID-19 Pandemic
- Chapter 11
Assessment of Vaccine Hesitancy to a COVID-19 Vaccine in Cameroonian Adults and Its Global Implication
- Chapter 12
mRNA Vaccines to Prevent COVID-19 Disease and Reported Allergic Reactions Current Evidence and Suggested Approach
- Chapter 13
High Rates of COVID-19 Vaccine Hesitancy and Its Association with Conspiracy Beliefs A Study in Jordan and Kuwait among Other Arab Countries
- Chapter 14
Immunological considerations for COVID-19 vaccine strategies
- Chapter 15
Progress and Pitfalls in the Quest for Effective SARS-CoV-2 (COVID-19) Vaccines
Readership:
Students, academics, teachers and other people attending or interested in COVID-19 Vaccine.
Mangalakumari Jeyanathan
Mangalakumari Jeyanathan
McMaster Immunology Research Centre, McMaster University, Hamilton, ON, Canada.
Brian D Lichty
Brian D Lichty
McMaster Immunology Research Centre, McMaster University, Hamilton, ON, Canada.
Aleena Banerji
Aleena Banerji
Division of Rheumatology, Allergy and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, Mass; Harvard Medical School, Boston, Mass.
David A Khan
David A Khan
Division of Allergy & Immunology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas.
Saman Soleimanpour
Saman Soleimanpour
Antimicrobial Resistance Research Center, Bu-Ali Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
and more...